Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.84
TRIB's Cash to Debt is ranked lower than
63% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. TRIB: 0.84 )
Ranked among companies with meaningful Cash to Debt only.
TRIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.99 Max: No Debt
Current: 0.84
Equity to Asset 0.58
TRIB's Equity to Asset is ranked lower than
53% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TRIB: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
TRIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.74 Max: 0.88
Current: 0.58
0.29
0.88
Interest Coverage 2.13
TRIB's Interest Coverage is ranked lower than
91% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. TRIB: 2.13 )
Ranked among companies with meaningful Interest Coverage only.
TRIB' s Interest Coverage Range Over the Past 10 Years
Min: 0.73  Med: 149.3 Max: 1315.33
Current: 2.13
0.73
1315.33
F-Score: 5
Z-Score: 2.22
WACC vs ROIC
9.18%
5.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 9.94
TRIB's Operating margin (%) is ranked higher than
69% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. TRIB: 9.94 )
Ranked among companies with meaningful Operating margin (%) only.
TRIB' s Operating margin (%) Range Over the Past 10 Years
Min: -56.78  Med: 12.14 Max: 67.5
Current: 9.94
-56.78
67.5
Net-margin (%) 3.04
TRIB's Net-margin (%) is ranked higher than
59% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. TRIB: 3.04 )
Ranked among companies with meaningful Net-margin (%) only.
TRIB' s Net-margin (%) Range Over the Past 10 Years
Min: -55.5  Med: 13.49 Max: 67.4
Current: 3.04
-55.5
67.4
ROE (%) 1.45
TRIB's ROE (%) is ranked higher than
55% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. TRIB: 1.45 )
Ranked among companies with meaningful ROE (%) only.
TRIB' s ROE (%) Range Over the Past 10 Years
Min: -76.72  Med: 9.84 Max: 54.77
Current: 1.45
-76.72
54.77
ROA (%) 0.86
TRIB's ROA (%) is ranked higher than
59% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. TRIB: 0.86 )
Ranked among companies with meaningful ROA (%) only.
TRIB' s ROA (%) Range Over the Past 10 Years
Min: -45.03  Med: 7.29 Max: 41.2
Current: 0.86
-45.03
41.2
ROC (Joel Greenblatt) (%) 12.97
TRIB's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. TRIB: 12.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TRIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -123.61  Med: 30.95 Max: 125.23
Current: 12.97
-123.61
125.23
Revenue Growth (3Y)(%) -1.70
TRIB's Revenue Growth (3Y)(%) is ranked lower than
62% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. TRIB: -1.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TRIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.9  Med: -1.7 Max: 108.2
Current: -1.7
-30.9
108.2
EBITDA Growth (3Y)(%) 4.60
TRIB's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TRIB: 4.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TRIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.7  Med: 3.1 Max: 125.1
Current: 4.6
-45.7
125.1
EPS Growth (3Y)(%) -15.70
TRIB's EPS Growth (3Y)(%) is ranked lower than
66% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. TRIB: -15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TRIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.9  Med: -5.75 Max: 75.7
Current: -15.7
-52.9
75.7
» TRIB's 10-Y Financials

Financials (Next Earnings Date: 2017-03-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

TRIB Guru Trades in Q4 2015

Chuck Royce 702,598 sh (+17.87%)
Zeke Ashton Sold Out
Jim Simons 202,065 sh (-7.82%)
» More
Q1 2016

TRIB Guru Trades in Q1 2016

Chuck Royce 799,098 sh (+13.73%)
Jim Simons 194,150 sh (-3.92%)
» More
Q2 2016

TRIB Guru Trades in Q2 2016

Chuck Royce 779,098 sh (-2.50%)
Jim Simons 162,550 sh (-16.28%)
» More
Q3 2016

TRIB Guru Trades in Q3 2016

Jim Simons 237,450 sh (+46.08%)
Chuck Royce 439,130 sh (-43.64%)
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:RDNT, AMEX:SENS, NYSE:ENZ, NYSE:NVTA, NAS:OXFD, NAS:SRDX, NAS:ONVO, NAS:LNTH, NAS:TTOO, NAS:CTSO, NAS:PMD, NAS:QTNT, AMEX:VNRX, NAS:HSKA, OTCPK:EPGNF, NAS:NVDQ, NAS:TROV, NAS:NRCIA, NAS:CEMI, NAS:CDNA » details
Traded in other countries:TRBA.Germany,
Trinity Biotech PLC develops, acquires, manufactures & markets medical diagnostic products for clinical laboratory & point-of-care of diagnostic market. Its products are used to detect autoimmune, infectious, diabetes and disorders of liver & intestine.

Trinity Biotech PLC was incorporated as a public limited company, registered in Ireland in January 1992. The Company commenced operations in 1992 and, in October 1992, completed an initial public offering of its securities in USA. The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. Its products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. It is also a provider of raw materials to the life sciences industry. The Company markets its portfolio of almost 850 products to customers in approximately 100 countries around the world through its own sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's tests remains the USA. The Company develops, acquires, manufactures and markets clinical in-vitro diagnostic products. It supplies the clinical laboratory segment of the in-vitro diagnostic market. It also sells raw materials to the life sciences industry. Its Point-of-Care product is Unigold (tm), which tests for the presence of HIV antibodies. It sells its product through its own direct sales-force in four countries: the United States, Germany, France and the United Kingdom. Its competitors are Abbott Diagnostics, Alere Inc., Arkray, Bio-Rad, Diasorin Inc., Euroimmun, Johnson & Johnson, OraSure Technologies Inc., Phadia, Roche Diagnostics, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen. The preclinical and clinical testing, manufacture, labelling, distribution, and promotion of Trinity Biotech's products are subject to extensive and rigorous government regulation in the United States and in other countries in which its products are sought to be marketed.

Ratios

vs
industry
vs
history
P/E(ttm) 57.80
TRIB's P/E(ttm) is ranked lower than
84% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. TRIB: 57.80 )
Ranked among companies with meaningful P/E(ttm) only.
TRIB' s P/E(ttm) Range Over the Past 10 Years
Min: 2.08  Med: 21.43 Max: 114.19
Current: 57.8
2.08
114.19
PE(NRI) 57.80
TRIB's PE(NRI) is ranked lower than
84% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. TRIB: 57.80 )
Ranked among companies with meaningful PE(NRI) only.
TRIB' s PE(NRI) Range Over the Past 10 Years
Min: 2.08  Med: 21.27 Max: 111.33
Current: 57.8
2.08
111.33
P/B 0.94
TRIB's P/B is ranked higher than
93% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. TRIB: 0.94 )
Ranked among companies with meaningful P/B only.
TRIB' s P/B Range Over the Past 10 Years
Min: 0.23  Med: 1.36 Max: 6.89
Current: 0.94
0.23
6.89
P/S 1.92
TRIB's P/S is ranked higher than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TRIB: 1.92 )
Ranked among companies with meaningful P/S only.
TRIB' s P/S Range Over the Past 10 Years
Min: 0.16  Med: 2.54 Max: 7.02
Current: 1.92
0.16
7.02
POCF 11.56
TRIB's POCF is ranked higher than
74% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.55 vs. TRIB: 11.56 )
Ranked among companies with meaningful POCF only.
TRIB' s POCF Range Over the Past 10 Years
Min: 1.84  Med: 17.22 Max: 442.86
Current: 11.56
1.84
442.86
EV-to-EBIT 21.52
TRIB's EV-to-EBIT is ranked higher than
55% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. TRIB: 21.52 )
Ranked among companies with meaningful EV-to-EBIT only.
TRIB' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.7  Med: 16.05 Max: 75.8
Current: 21.52
-1.7
75.8
EV-to-EBITDA 21.52
TRIB's EV-to-EBITDA is ranked lower than
62% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. TRIB: 21.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
TRIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.7  Med: 16.05 Max: 75.8
Current: 21.52
-1.7
75.8
Shiller P/E 33.20
TRIB's Shiller P/E is ranked higher than
69% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.25 vs. TRIB: 33.20 )
Ranked among companies with meaningful Shiller P/E only.
TRIB' s Shiller P/E Range Over the Past 10 Years
Min: 1.38  Med: 20.01 Max: 184.73
Current: 33.2
1.38
184.73
Current Ratio 7.27
TRIB's Current Ratio is ranked higher than
89% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TRIB: 7.27 )
Ranked among companies with meaningful Current Ratio only.
TRIB' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 3.23 Max: 9.17
Current: 7.27
1
9.17
Quick Ratio 5.35
TRIB's Quick Ratio is ranked higher than
84% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. TRIB: 5.35 )
Ranked among companies with meaningful Quick Ratio only.
TRIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.63 Max: 7.6
Current: 5.35
0.44
7.6
Days Inventory 241.61
TRIB's Days Inventory is ranked lower than
92% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. TRIB: 241.61 )
Ranked among companies with meaningful Days Inventory only.
TRIB' s Days Inventory Range Over the Past 10 Years
Min: 180.54  Med: 207.68 Max: 241.61
Current: 241.61
180.54
241.61
Days Sales Outstanding 96.30
TRIB's Days Sales Outstanding is ranked lower than
78% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. TRIB: 96.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.9  Med: 68.53 Max: 96.3
Current: 96.3
47.9
96.3

Buy Back

vs
industry
vs
history
Dividend Growth (3y) 13.60
TRIB's Dividend Growth (3y) is ranked higher than
69% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.30 vs. TRIB: 13.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TRIB' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.1
Current: 13.6
0
30.1
Yield on cost (5-Year) 2.01
TRIB's Yield on cost (5-Year) is ranked higher than
64% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. TRIB: 2.01 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TRIB' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.72  Med: 1.05 Max: 2.33
Current: 2.01
0.72
2.33
3-Year Average Share Buyback Ratio -2.50
TRIB's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. TRIB: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TRIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86.4  Med: -4 Max: 30.2
Current: -2.5
-86.4
30.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 138.80
TRIB's Price/Net Current Asset Value is ranked lower than
97% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. TRIB: 138.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TRIB' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.61  Med: 4.64 Max: 320
Current: 138.8
0.61
320
Price/Tangible Book 5.30
TRIB's Price/Tangible Book is ranked lower than
53% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. TRIB: 5.30 )
Ranked among companies with meaningful Price/Tangible Book only.
TRIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.4  Med: 2.7 Max: 250
Current: 5.3
0.4
250
Price/Projected FCF 1.39
TRIB's Price/Projected FCF is ranked higher than
64% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. TRIB: 1.39 )
Ranked among companies with meaningful Price/Projected FCF only.
TRIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.28  Med: 1.32 Max: 78.33
Current: 1.39
0.28
78.33
Price/Median PS Value 0.76
TRIB's Price/Median PS Value is ranked higher than
71% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. TRIB: 0.76 )
Ranked among companies with meaningful Price/Median PS Value only.
TRIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 0.66 Max: 3.21
Current: 0.76
0.09
3.21
Price/Graham Number 3.69
TRIB's Price/Graham Number is ranked lower than
58% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. TRIB: 3.69 )
Ranked among companies with meaningful Price/Graham Number only.
TRIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.27  Med: 1.23 Max: 10.23
Current: 3.69
0.27
10.23
Earnings Yield (Greenblatt) (%) 4.66
TRIB's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TRIB: 4.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TRIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 5.4 Max: 84.7
Current: 4.66
1.3
84.7
Forward Rate of Return (Yacktman) (%) -9.90
TRIB's Forward Rate of Return (Yacktman) (%) is ranked lower than
90% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.71 vs. TRIB: -9.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TRIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -30.9  Med: -2.4 Max: 2.5
Current: -9.9
-30.9
2.5

More Statistics

Revenue (TTM) (Mil) $100.9
EPS (TTM) $ 0.12
Beta1.16
Short Percentage of Float3.04%
52-Week Range $5.76 - 13.68
Shares Outstanding (Mil)23.96

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 102 104
EPS ($) 0.29 0.29
EPS w/o NRI ($) 0.29 0.29
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for TRIB

Headlines

Articles On GuruFocus.com
Zeke Ashton Sells Greenlight Capital and Vector Group, Buys Parker and Alphabet Nov 23 2015 

More From Other Websites
Is American Public Education, Inc. (APEI) a Good Stock to Buy? Dec 09 2016
Is Trinity Biotech plc (ADR) (TRIB) A Good Stock To Buy? Dec 08 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities... Oct 31 2016
Trinity Biotech Plc :TRIB-US: Earnings Analysis: Q3, 2016 By the Numbers : October 26, 2016 Oct 26 2016
Edited Transcript of TRIB earnings conference call or presentation 25-Oct-16 3:00pm GMT Oct 25 2016
Trinity Biotech Announces Q3 2016 Financial Results Oct 25 2016
Trinity Biotech reports 3Q loss Oct 25 2016
Trinity Biotech reports 3Q loss Oct 25 2016
Trinity Biotech announces Quarter 3 Financial Results Oct 25 2016
Q3 2016 Trinity Biotech PLC Earnings Release - Time Not Supplied Oct 25 2016
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Trinity Biotech plc and... Oct 19 2016
trinity-biotech-to-announce-q3-2016-results Oct 12 2016
Trinity Biotech plc to Announce Third Quarter Fiscal Year 2016 Financial Results Oct 12 2016
[$$] Trinity Biotech: Think Twice if Bottom-Fishing Oct 12 2016
5 Companies That Destroyed Shareholders This Past Week Oct 08 2016
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Trinity Biotech plc and... Oct 06 2016
INVESTOR ALERT: Investigation of Trinity Biotech plc Announced by Law Offices of Howard G. Smith Oct 06 2016
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Trinity Biotech plc and Advises... Oct 05 2016
TRINITY NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... Oct 05 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities... Oct 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)